Innovative computational and AI-driven methods are unlocking novel drug discovery pathways. David Baker's lab has engineered AI approaches to design binders targeting intrinsically disordered proteins, previously considered undruggable, expanding therapeutic options for diseases linked to flexible protein structures. Complementing this, researchers at Oregon Health & Science University developed OmicsTweezer, a machine learning model integrating bulk and single-cell multi-omics data to accurately elucidate tumor microenvironments, enhancing cancer research and treatment strategies. Such technologies represent a leap forward in precision oncology and protein engineering.